JP7309214B2 - 抗菌性物質として有益なジフェニル置換チオフェン－２－アミド誘導体およびそれらの医薬組成物 - Google Patents

抗菌性物質として有益なジフェニル置換チオフェン－２－アミド誘導体およびそれらの医薬組成物 Download PDF

Info

Publication number
JP7309214B2
JP7309214B2 JP2020545178A JP2020545178A JP7309214B2 JP 7309214 B2 JP7309214 B2 JP 7309214B2 JP 2020545178 A JP2020545178 A JP 2020545178A JP 2020545178 A JP2020545178 A JP 2020545178A JP 7309214 B2 JP7309214 B2 JP 7309214B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
compounds
microbial infection
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516680A5 (enExample
JP2021516680A (ja
Inventor
ウー，ファン
ルー，エーフ
スン，シェンゴー
ジェイ． バーデン，クリストファー
Original Assignee
デノバメド インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デノバメド インク． filed Critical デノバメド インク．
Publication of JP2021516680A publication Critical patent/JP2021516680A/ja
Publication of JP2021516680A5 publication Critical patent/JP2021516680A5/ja
Application granted granted Critical
Publication of JP7309214B2 publication Critical patent/JP7309214B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020545178A 2018-03-05 2019-03-01 抗菌性物質として有益なジフェニル置換チオフェン－２－アミド誘導体およびそれらの医薬組成物 Active JP7309214B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862638832P 2018-03-05 2018-03-05
US62/638,832 2018-03-05
US201862727809P 2018-09-06 2018-09-06
US62/727,809 2018-09-06
PCT/CA2019/050242 WO2019169479A1 (en) 2018-03-05 2019-03-01 Diphenyl substituted thiophene-2-amide derivatives and pharmaceutical compositions thereof useful as antimicrobial

Publications (3)

Publication Number Publication Date
JP2021516680A JP2021516680A (ja) 2021-07-08
JP2021516680A5 JP2021516680A5 (enExample) 2022-03-09
JP7309214B2 true JP7309214B2 (ja) 2023-07-18

Family

ID=67846467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020545178A Active JP7309214B2 (ja) 2018-03-05 2019-03-01 抗菌性物質として有益なジフェニル置換チオフェン－２－アミド誘導体およびそれらの医薬組成物

Country Status (7)

Country Link
US (1) US11306067B2 (enExample)
EP (1) EP3762376B1 (enExample)
JP (1) JP7309214B2 (enExample)
CN (1) CN112166109B (enExample)
CA (1) CA3092144A1 (enExample)
ES (1) ES2942848T3 (enExample)
WO (1) WO2019169479A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113855680B (zh) * 2021-09-02 2023-11-03 四川农业大学 肉桂醛联合头孢曲松钠的应用
JP2025511361A (ja) * 2022-04-05 2025-04-15 デノバメド インク． 抗菌性の４，５ ジアリール－チオフェン－２－イル ヘキサフルオロプロパン－２－ｏｌｓ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508279A (ja) 2003-10-10 2007-04-05 サノフィ−アベンティス チオフェン−２−カルボキサミド誘導体、それらの製造、および治療適用
JP2014506895A (ja) 2011-03-03 2014-03-20 デノバメド インク． 抗菌性の化合物／アジュバント化合物および方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1011949A (en) 1964-10-27 1965-12-01 Vacu Blast Ltd Centrifugal wheel blasting machine
US3527864A (en) 1966-11-18 1970-09-08 Procter & Gamble Compositions for topical application to animal tissue and method of enhancing penetration thereof
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3903256A (en) 1972-02-07 1975-09-02 Procter & Gamble Compositions for topical application of animal tissue and method of enhancing penetration thereof
US3896238A (en) 1972-04-05 1975-07-22 Procter & Gamble Dermatological compositions
US3952099A (en) 1973-03-13 1976-04-20 The Procter & Gamble Company Dermatological compositions
US4046886A (en) 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4130643A (en) 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4335115A (en) 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
JPS57134480A (en) * 1980-12-29 1982-08-19 Du Pont Antiinflammatory 4,5-diaryl-alpha- (polyhalomethyl)-2-thiophene methanols
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4343798A (en) 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4820720A (en) 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
US4863738A (en) 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5378730A (en) 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508279A (ja) 2003-10-10 2007-04-05 サノフィ−アベンティス チオフェン−２−カルボキサミド誘導体、それらの製造、および治療適用
JP2014506895A (ja) 2011-03-03 2014-03-20 デノバメド インク． 抗菌性の化合物／アジュバント化合物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.G.WERMUTH編，『最新 創薬化学 上巻』，株式会社テクノミック，1998年08月15日，235-271頁，13章 等価置換に基づく分子の変換

Also Published As

Publication number Publication date
EP3762376B1 (en) 2023-03-01
CA3092144A1 (en) 2019-09-12
CN112166109B (zh) 2023-09-12
ES2942848T3 (es) 2023-06-07
EP3762376A4 (en) 2021-10-20
EP3762376A1 (en) 2021-01-13
WO2019169479A1 (en) 2019-09-12
JP2021516680A (ja) 2021-07-08
US20210017147A1 (en) 2021-01-21
CN112166109A (zh) 2021-01-01
US11306067B2 (en) 2022-04-19

Similar Documents

Publication Publication Date Title
EP2651419B1 (en) A composition comprising an antibiotic and a dispersant
JP5410748B2 (ja) 抗菌剤およびカルベオール、チモール、オイゲノール、ボルネオールならびにカルバクロールから選択される活性成分を含んでなる医薬組成物
US9012655B2 (en) Antimicrobial/adjuvant compounds and methods
CA2818100C (en) Compounds and their use
US20130296228A1 (en) Efflux pump inhibitors
WO2013139861A1 (en) Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US11306067B2 (en) Diphenyl substituted thiophene-2-amide derivatives and pharmaceutical compositions thereof useful as antimicrobial
KR20230162654A (ko) 반코마이신과 조합된 리파마이신 유사체 및 이의 용도
WO2023193101A1 (en) Antibacterial 4,5 diaryl-thiophen-2-yl hexafluoropropan-2-ols
JP6178224B2 (ja) 併用抗メチシリン耐性黄色ブドウ球菌薬、及びβラクタム系抗生物質の抗菌活性増強剤
CN121181578A (zh) 一种噻唑喹啉酮类化合物及其应用
HK1220911B (en) A composition comprising a non-peptide antibiotic and cysteamine
HK1185015B (en) A composition comprising an antibiotic and a dispersant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230216

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230628

R150 Certificate of patent or registration of utility model

Ref document number: 7309214

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250